Jay Mohr is an experienced C-level executive in the biopharmaceutical industry, focusing on cellular therapy and hematology. Currently, they serve as General Partner at NYBC Ventures and EVP, Chief Business Officer at the New York Blood Center, where they lead business development and venture investments. Mohr has a history of founding and leading organizations, including Gloucester Pharmaceuticals, which gained FDA approval for a rare hematologic cancer treatment and was acquired by Celgene for $640 million. They hold a BA in Economics and German from Vanderbilt University and an MBA from The Wharton School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices